16 November, 2005 22:43 GMT
The latest tests of the drug Actos, prescribed to treat diabetes, show that it also lowers the combined risk of heart attacks, strokes and death.
The
American Heart Association says new data indicate the drug Actos reduced heart attacks by 28 percent in people with type 2 diabetes.
The results from secondary analyses of the landmark PROactive Study found Actos -- pioglitazone HCl -- significantly reduced the occurrence of heart attacks and acute coronary syndrome in high-risk patients with type 2 diabetes who had suffered a previous heart attack.
Researchers said the results were beyond those seen with standard of care treatment.
Builds on Earlier Results
The findings were announced Wednesday during the AHA's Scientific Sessions meeting in Dallas.
Researchers said the study builds on previously reported results showing Actos, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk patients with type 2 diabetes.
Actos is produced by the
Takeda Pharmaceutical Co. of Osaka, Japan, and is licensed by Takeda Pharmaceuticals North America Inc. and Eli Lilly and Company.
 |
Home 
